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1. Introduction
Neuroendocrine tumours (NETs) are rare and heterogeneous neoplasms with variable bio‐
logical behaviour. The estimated incidence of NETs is about 1-5 cases/100,000/year. The
most recent data show a progressive increase of the incidence in the last years and a high
increase of their prevalence and survival [1]. NETs can be sporadic or can arise in complex
hereditary endocrine disorders such as Multiple Endocrine Neoplasias (MENs), Familial
Paragangliomatosis (FPGLs), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease
(VHL), Tuberous Sclerosis (TSC) [1]. It has been estimated that hereditary NETs occurrence
varies with site of origin of the tumour, ranging 5 to 30% of cases [1]. Due to the recent ad‐
vances in the knowledge of biology and genetics of NETs, these rates seems to be an under‐
estimation and novel mutations of well known oncogenes or tumour suppressor genes as
well as new genes and molecular pathways responsible for unknown syndromes are expect‐
ed to be characterized.
Patients with hereditary NET syndromes inherit the susceptibility to develop multiple endo‐
crine neoplasias which can be associated with non-endocrine tumours and/or non-tumour
lesions. They are characterized by germline mutations usually inherited as an autosomal
dominant disease according to the Knudson’s “two-hits hypothesis” [2].
Compared to the sporadic forms, hereditary NETs generally present an earlier age at onset,
multiple tumour localizations, higher secretory activity. Diagnosis is made around sixth dec‐
ade of life in sporadic NETs while it is anticipated of about three decades in hereditary tu‐
mours [3]. The identification of hereditary NET syndromes is relevant to achieve a
precocious diagnosis and this may be important to prevent severe complications and unfav‐
ourable outcome. For this reason, the genetic screening is nowadays a well established pro‐
cedure in many tumor types allowing to reclassify as carrier of specific hereditary NET
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syndromes, a number of patients with an apparently sporadic tumours [4]. Some studies, fo‐
cusing in particular on MEN type 1, highlighted that the genetic screening impacts on the
management and clinical outcome of NETs, because it allows to detect tumours at an early
stage or even before their development [5-7].
In spite of these recent advances, at now, clinical pictures of most of the hereditary NET syn‐
dromes are incomplete or not updated. In addition, follow-ups of these patients are not
standardized. Furthermore, although in the last years it has been possible to identify a lot of
genes and molecular pathways responsible for the development of hereditary NETs, many
other molecular pathways responsible for apparently sporadic NETs or influencing the phe‐
notype of well known hereditary NETs remain to be detected and characterized.
In summary, the genetic origin influences the natural history of NETs, however, natural his‐
tory and clinical course of hereditary NETs is not well defined for most of the actually
known hereditary NET syndromes and other syndromes remained to be discovered.
In this chapter two hereditary endocrine syndromes (Multiple Endocrine Neoplasias and
Familial Paragangliomatosis) will be discussed.
2. Epidemiology and clinical characteristics
2.1. Multiple Endocrine Neoplasias
Multiple Endocrine Neoplasias (MENs) are rare hereditary autosomal dominant syndromes
with complete penetrance and variable expressivity, characterized by the onset of various
endocrine and non endocrine tumors with different localization. We distinguish the MEN
type 1 (MEN1) and MEN type 2 (MEN2) that are two distinct syndromes.
2.1.1. MEN1
MEN1 or Wermer’s Syndrome (OMIM #131100) is characterized by high penetrance (more
than 95% of carriers develop disease within 50 years of age), variable inter- and intra-fami‐
lial expressivity and genetic anticipation [3, 8]. It has been estimated that the prevalence of
MEN1 is 2-3:100,000 individuals, with the same distribution between males and females [9].
MEN1 is characterized by the occurrence of tumors of the parathyroid glands, the anterior
pituitary, the pancreatic islets and the adrenal glands, as well NETs in the foregut (thymic,
bronchial and gastric carcinoids). Other non-endocrine tumors can associate in the skin (an‐
giofibromas, lipomas, collagenomas) and in the central nervous system (ependimoma, men‐
ingioma) (Table 1). According to the MEN Consensus published in 2001, the clinical
diagnosis of this syndrome is based on the concomitant occurrence of at least two of the
three MEN1-related endocrine tumors (parathyroid adenoma, pituitary adenoma, duodeno-
pancreatic-NET). Familial MEN1 is defined as at least one MEN1-related NET plus at least
one first-degree relative with at least one of the three classical tumors or a known germline
MEN1 mutation [10].
Hot Topics in Endocrine and Endocrine-Related Diseases2
Endocrine tumors %
Parathyroid glands 75-95
Pancreatic islets 55
Gastrinomas 45
Insulinomas 10
Non-functioning 10
Other (VIPomas, etc.) 2
Pituitary 47
PRLomas 30
Non-functioning 10
ACTHomas 1
GH-omas 3-6
Adrenal cortical 20
Foregut 18
Thymus 8
Lungs 8
Stomach 5
Non-endocrine tumors
Skin 80
Angiofibromas 75
Collagenomas 5
Lipomas 30
Leiomyomas 5
CNS (meningiomas) 25
ACTH: adrenocorticotrophic hormone; CNS: central nervous sys‐
tem; GH: growth hormone; PRL: prolactin; VIP: vasoactive intesti‐
nal peptide.
Table 1. Endocrine and non-endocrine tumors associated to Multiple Endocrine Neoplasia type 1
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Typically, NETs associated to MEN1 rise up two decades before the sporadic ones. They
are  generally  benign;  however,  both  duodeno-pancreatic  NETs  and  carcinoids  can  be
malignant.
Hyperparathyroidism, caused by parathyroid adenoma/hyperplasia, is often the first mani‐
festation of MEN1. About 75-95% of MEN1 patients develop parathyroid adenomas [10].
Usually parathyroid adenomas are multiple and benign. The main clinical manifestations of
primary hyperparathyroidism and the resulting hypercalcemia are represented by renal dis‐
eases (dehydration, hypercalciuria, nephrolithiasis and, in advanced cases, kidney failure),
bone changes (early osteopenia/osteoporosis), neurological manifestations (drowsiness, de‐
pression, confusion), gastrointestinal disturbances (anorexia, constipation, nausea, vomit‐
ing) and cardiovascular alterations (hypertension, short QT-trait).
Laboratory investigation to detect primary hyperparathyroidism consist of measurement of
(ionized) calcium, phosphate and parathyroid hormone in blood and the 24-hour calcium
excretion in the urine. Bone densitometry can be used to detect bone mass reduction. Para‐
thyroid adenomas can be localized by neck ultrasonography (US) and Tc-99m sestamibi
scintigraphy (useful to detect also ectopic parathyroid glands).
Pancreatic endocrine tumors develop in about 55% of MEN1 patients [11]. Pancreatic tumor
in the context of MEN1 is, generally, multicentric with considerable variability in size (mi‐
cro-and macro-tumors) and clinical behavior (lesion localized, invasive or metastatic). Multi‐
centric microadenomas are present in 90% of MEN1 patients [12]. It is common to detect
functioning NETs associated with non-functioning NETs. The main locations of occurrence
are represented by the pancreas in toto and the duodenal submucosa. In order of frequency,
the duodeno-pancreatic NETs associated with the syndrome of gastrin hypersecretion are
the most frequent and are responsible for the Zollinger-Ellison syndrome. Functioning syn‐
dromes and related symptoms are shown in Table 2.
Hormonal syndromes often occur late and may indicate metastases in 50% of MEN1 pa‐
tients [13].
Laboratory investigation to detect duodeno-pancreatic NETs includes specific markers (such
as gastrin, insulin, glucose, glucagon) and the aspecific marker cromogranin-A. Duodeno-
pancreatic NETs can be detected by US and echo-endoscopy, magnetic resonance imaging
(MRI), computed tomography (CT) and functional imaging techniques such as somatostain
receptor scintigraphy.
Pituitary adenomas are found in about 50% of MEN1 patients and evidence of MEN1 is
found in approximately 2.7% of patients with pituitary adenomas [10]. Pituitary tumors in
MEN1, compared to sporadic tumors, are larger in size and more aggressive. Since child‐
hood MEN1 subjects need to be evaluated for pituitary tumors [14].
The diagnosis of functioning pituitary adenoma is confirmed by determining a specific hor‐
mone excess on blood or urinary samples. Pituitary adenomas can be detect visually by MRI
with gadolinium contrast.
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Syndrome Symptoms
Zollinger-Ellison syndrome
(gastrin hypersecretion)
Pain or burning sensation in the abdomen
Nausea
Vomiting
Diarrhea
Fatigue
Weakness
Weight loss
Insulinoma syndrome Anxiety
Behavior changes
Clouded vision
Confusion
Convulsions
Dizziness
Headache
Hunger
Loss of consciousness
Rapid heart rate
Sweating
Tremor
Weight gain
Verner-Morrison syndrome
(VIP hypersecretion)
Abdominal pain and cramping
Diarrhea (watery, and often in large amounts)
Flushing or redness of the face
Nausea
Weight loss
Somatostatinoma syndrome Mild diabetes mellitus
Steatorrhoea
Gall stones
Glucagonoma syndrome Anemia
Diarrhea
Weight loss
Necrolytic migratory erythema
Diabetes mellitus
Table 2. Functioning syndromes and related symptoms associated to Multiple Endocrine Neoplasia type 1
2.1.2. MEN2
MEN2 or Sipple’s Syndrome (OMIM #171400) is an autosomal dominant disease resulting
from germline mutations of the RET proto-oncogene, with an estimated prevalence of
1:30,000 subjects [10]. It is divided in three clinical variants: a) MEN2A (medullary thyroid
cancer, pheochromocytoma, primary hyperparathyroidism and cutaneous lichen amyloido‐
sis or Hirschsprung disease); b) familial medullary thyroid cancer (FMTC); c) MEN2B (me‐
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dullary thyroid cancer, pheochromocytoma, mucosal and intestinal ganglioneuromatosis,
marfanoid habitus) [10, 15, 16]. Although these variants have medullary thyroid cancer as a
common denominator, they differ for the aggressiveness of this cancer, in a decreasing order
MEN2B>MEN2A>FMTC [15]. In patients with FMTC, medullary thyroid cancer (MTC) is
the only clinical manifestation. According to the “International RET Mutation Consostium”,
to make the diagnosis of FMTC is required the onset of medullary thyroid cancer (MTC) in
at least four family members [17]. About 56% of cases belong to the subtype 2A, while the
subtype 2B is the most aggressive with an elevated morbidity and mortality [15, 16, 18].
Plasma free metanephrines have the highest sensitivity and specificity for detecting pheo‐
chromocytoma. However, measurement of 24-hour urine catecholamines and metanephr‐
ines, and serum catecholamines are also frequently used [19, 20]. Imaging techniques
include abdomen CT-scan and/or MRI. Functional imaging techniques include somatostatin
receptor scintigraphy and metaiodobenzylguanidine (MIBG) scintigraphy.
2.2. Familial paragangliomatosis
Familial Paragangliomatosis (FPGLs) are hereditary syndromes of susceptibility to multiple
neuroectodermal tumors characterized by high vascularisation and slow growth that arise
from the medullar of adrenal glands (pheochromocytomas, PCCs) or from extra-adrenal
ganglia (paragangliomas, PGLs).
PCCs and PGLs occur as sporadic tumors and in 10-50% of cases the tumors were associated
with hereditary syndromes, mainly MEN2, von Hippel–Lindau disease (VHL), and neurofi‐
bromatosis type 1 (NF1) [21]. A small fraction is associated with other syndromes, including
Carney triad, Carney–Stratakis syndrome, and, very rarely, MEN1.
There are four subtypes of FPGLs. PGLs can found in all three types of FPGL while phaeo‐
chromocytomas are very rare in the FPGL3 [22].
Hereditary PCCs/PGLs, in comparison to sporadic ones, arise more prematurely, can be bi‐
lateral or multifocal and can more frequently relapse.
About 10% of the PCCs/PGLs is malignant. FPGL4 is characterized by an increase chance of
malignant paragangliomas; in this disorder, then, renal cell cancers and thyroid cancers can
be found [22].
Pheochromocytomas and sympathetic paragangliomas result in hypersecretion of catechola‐
mines, which can cause headache, palpitations, hypertension, tachycardia and excessive per‐
spiration, as well as many other nonspecific symptoms. Although most pheochromocytomas
and paragangliomas are benign, they can cause major morbidity and death due to uncon‐
trolled hypertension precipitated by stressful events such as anesthesia and pregnancy. Par‐
asympathetic paraganglioma are typically located within the head and neck and usually do
not secrete excess catecholamines. They generally do not present symptomatically unless
there is a mass effect causing a visible or palpable mass.
Laboratory tests include plasma free metanephrines, 24-hour urine catecholamines and met‐
anephrines.
Hot Topics in Endocrine and Endocrine-Related Diseases6
Imaging  techniques  include  neck,  skull  base  and  abdomen/pelvis  CT-scan  and/or  MRI.
Functional imaging techniques include somatostatin rceptor scintigraphy and MIBG scin‐
tigraphy.
3. Genetic pathways and pathophysiology of mutations
The genetic origin influences the natural history of NETs. This is particularly evident in
MEN1 where the diagnosis is made around the sixth decade of life in sporadic tumors while
it is anticipated of about three decades in hereditary tumors [3, 10]. The identification of he‐
reditary NET syndromes is relevant to achieve a precocious diagnosis of the tumors and this
may be important to prevent severe complications and unfavourable outcome. In the last
years, it has been possible to identify a number of genes and molecular pathways involved
in the development of NETs. Of consequence, some patients with apparently sporadic tu‐
mor have been reclassified as carriers of hereditary NET with relevant implications on the
clinical course of disease and quality of life.
3.1. Multiple Endocrine Neoplasias
3.1.1. MEN1
MEN1 is an autosomal dominant syndrome resulting from an inactivating germline muta‐
tion of the MEN1 gene located on chromosome 11q13 [23].
Up to 80% of MEN1-associated tumors exhibit loss of heterozigosity (LOH) of 11q13, indi‐
cating that MEN1 functions as a tumor suppressor gene.
Approximately 21% of sporadic pancreatic neuroendocrine tumors (PNETs) harbour muta‐
tions in MEN1, but there is substantial variation across different tumor subtypes. Whereas
only 8% of insulinomas and non-functioning PNETs have identifiable MEN1 mutations,
they are more frequent in gastrinomas [37%), VIPomas (44%) and glucagonomas (67%)
[24-31].In contrast to the relatively low frequency of MEN1 mutations in sporadic PNETs,
up to 68% display LOH at chromosome 11q13 [32].
This raises the possibility there may be other, yet to be identified, tumor suppressor genes
on the long arm of chromosome 11. Similarly, LOH of chromosome 11 is present in up to
78% of gastrointestinal carcinoids, but the frequency of MEN1 mutations is much lower.
Gortz et al. reported MEN1 mutations in 2/11 (18%) gastrointestinal carcinoids and 2/11
[18%) lung carcinoids [26] and Debelenko et al identified MEN1 mutations in 4/11 (36%)
lung carcinoids [33]. The MEN1 gene product, menin, is a nuclear protein that binds to
many transcription factors, including the AP1 component JunD. Upon binding to JunD, me‐
nin represses JunD-mediated transcription to inhibit cellular proliferation. Inactivating mu‐
tations of MEN1 disrupt the binding to JunD to enhance transcription and augment cellular
proliferation [34, 35]. More recently, menin was also identified in a complex with the MLL
histone methyltransferase that associates with regulatory elements in the promoters of the
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cell cycle inhibitors p27KIP1 and p18Ink4c to methylate histone H3 and enhance gene tran‐
scription [36]. In mouse models, the absence of Men1 results in down-regulation of p27KIP1
and p18Ink4c and a phenotype resembling the MEN1 syndrome, including islet-cell hyper‐
plasia [37, 38].
Of note, a similar phenotype was also observed in p27KIP1/p18Ink4c double-mutant mice
suggesting that deregulation of the cell cycle may be the critical consequence of MEN1 mu‐
tations and a necessary feature of NET pathogenesis in general [39]. Recently, the telomerase
(hTERT) gene was identified as a menin target gene. The end of chromosome in a cell, short‐
en after DNA replication. Eventually, after several cell divisions, the DNA loses its stability
and the cell is subjected to apoptosis. Telomerase is an enzyme that maintains the length of
the telomeres and is not expressed in normal cells, but it is active in stem cells and tumor
cells. Menin is a suppressor of the expression of the telomerase gene. Possibly, inactivation
of menin could lead to cell immortalization by telomerase expression, which could allow a
cell to develop into a tumor cell [40].
In approximately 10-15% of patients with a clinical diagnosis of MEN1 is not possible to
identify a known mutation, due to the presence of regulatory sequences inactivated. In such
cases the genetic analysis of first-degree relatives of patients with apparently negative fami‐
ly history can be helpful in identifying possible new mutations [41].
3.1.2. MEN2
MEN2 is dominantly inherited, and its genetic cause, mutations of the REarranged during
Transfection (RET) protooncogene, was first recognized nearly 20 years ago [10, 42-44].
Since then, the range of mutations identified, their potential for predicting clinical course,
and the underlying functional effects have been explored. Detection of RET mutations in
MEN2 represents a paradigm for genetically guided patient management, and genotype–
phenotype correlations in this disease now inform recommended interventions, patient and
family screening, and long-term follow-up [10, 45].
The RET proto-oncogene encodes a receptor tyrosine kinase that is required for the develop‐
ment of neural-crest derived cells, the urogenital system, and the central and peripheral
nervous systems, notably the enteric nervous system [46, 47].
The RET protein has a large extracellular domain containing a cysteine-rich region and a ser‐
ies of cadherin homology domains, a transmembrane domain, and an intracellular tyrosine
kinase domain, required for RET phosphorylation and downstream signalling [48, 49].
The RET kinase is structurally similar to other tyrosine kinases, sharing many conserved
functional motifs and regulatory residues that have been shown to have importance for kin‐
ase enzyme function [50]. RET is activated by binding of a multi-protein ligand complex.
RET binds a soluble ligand of the glial cell-line-derived neurotrophic factor (GDNF) family
but also requires a co-receptor of the GDNF family receptors a (GFRa), which is tethered to
the cell membrane via glycosylphosphatidylinositol linkage [51, 52]. Initially, GDNF binds
to GFRa, and these complexes are then able to recruit RET to form heterohexamers that are
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concentrated in regions of the cell membrane called lipid rafts These are membrane domains
enriched in glycosylphosphatidylinositol-linked proteins and signaling molecules that pro‐
vide a platform not only for enhanced cell signaling, but also for regulation of receptor kin‐
ase activity and down-regulation [53].
Activation of RET leads to stimulation of multiple downstream pathways, including mito‐
gen-activated protein kinase and extracellular signal-regulated kinase, phosphoinositide 3-
kinase and protein kinase B, signal transducer and activator of transcription 3, proto-
oncogene tyrosine-protein kinase Src1, and focal adhesion kinase that promote cell growth,
proliferation, survival, and/or differentiation [54, 55].
MEN2 is associated with point mutations of RET, predictably leading to its activation in the
absence of ligands and co-receptors. Mutations are primarily amino acid substitutions affect‐
ing a very small number of RET codons in either the extracellular domain or within the kin‐
ase domain.
Mutations are dominant, requiring only a single mutant allele to confer the disease pheno‐
type. MEN2 RET mutation occurrence [56-59] are available online (http://
www.arup.utah.edu/database/MEN2/MEN2_welcome.php). Together, these data suggest
strong overall themes as to functional effects of these mutations, but also as to their clinical
significance.
Together, these data suggest strong overall themes as to functional effects of these muta‐
tions, but also as to their clinical significance. Strong associations of disease subtype, and al‐
so specific disease phenotypes, with individual RET mutations have made it possible to
stratify risk of MEN2 by genotype [10, 45].
The management guidelines of the American Thyroid Association base the recommenda‐
tions for initial diagnosis, therapeutic intervention, and long-term follow-up on patient gen‐
otype and the current understanding of the natural history of the disease associated with
each RET mutation. Mutations of cysteine residues (primarily cysteines 609, 611, 618, 620,
630, and 634] in the RET extracellular domain account for the majority of MEN2A cases, and
are also common in patients with FMTC. Intracellular kinase domain mutations are mainly
associated with FMTC and MEN2B. Mutations in the intracellular codons 768, 790, 791, 804,
and 891 underlie FMTC, and occur less commonly in patients with MEN2A [60] while spe‐
cific mutations of codon 918 (M918T) or 883 (A883F) account for the vast majority of MEN2B
cases, and are exclusive to the subtype [61].
In addition to association with disease subtype, significant correlations of specific mutations
with disease features are reported. For example, RET codon 634 mutations carry a greater
patient risk for pheochromocytoma and parathyroid hyperplasia [62-64] and are associated
with a higher frequency of detection of MTC at the time of early thyroidectomy [65].
Variation in clinical presentation has even been observed with different codon 634 substitu‐
tions. The specific substitution of an arginine at codon 634 (C634R) is strongly associated
with increased risk of parathyroid hyperplasia increased frequency of distant metastases,
earlier onset of both lymph node and distant metastases, and bilaterality of pheochromocy‐
toma [66, 67].
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3.2. Hereditary pheochromocytoma/paraganglioma syndromes
During the last decade, mutations in the genes encoding different subunits of the succi‐
nate  dehydrogenase  (SDH)  complex  have  been  linked  to  familial  PCC/PGL  syndrome,
and subsequent genetic screenings have revealed that about 30% of PCCs and PGLs are
caused by  hereditary  mutations  [68,  69].  In  addition,  several  novel  susceptibility  genes,
such  as  kinesin  family  member  1B  (KIF1Bb)  [70],  EGL  nine  homolog  1,  also  termed
PHD2 (EGLN1/PHD2) [71],  transmembrane protein 127 (TMEM127) [72],  and MYC-asso‐
ciated factor X (MAX) [73], have recently been added to the list. The predisposing genes
that  have been identified seem at  a  first  glance to have entirely different  functions but,
in  spite  of  this,  malfunction  of  their  different  gene  products  can  give  rise  to  clinically
and histologically undistinguishable tumors.  Nevertheless,  some clinical features may be
quite different,  e.g.  patients with SDHB mutations have considerably higher risk of  ma‐
lignancy than many other PCC/PGL patients [74].
The feature of RET gene and MEN2 syndrome were previously described, we want to re‐
member that activating RET mutations predispose to PCCs, which are often recurrent and
bilateral, but typically have a low risk of malignancy.
Familial paragangliomatosis are associated to known germline mutations of the genes en‐
coding subunits of succinate dehydrogenase (SDH).
SDH  is  a  mitochondrial  enzyme  complex  consisting  of  four  subunits:  SDHA,  SDHB,
SDHC, and SDHD, which are all encoded by the nuclear genome [75]. The enzyme, also
known  as  mitochondrial  complex  II,  is  involved  both  in  the  tricarboxylic  acid  cycle,
where it catalyzes the oxidation of succinate to fumarate, and in the respiratory electron
transfer chain, where it transfers electrons to coenzyme Q. The gene SDHA is located on
chromosome 5p15.33  and consists  of  15  exons.  It  encodes  a  protein  that  functions  as  a
part  of  the  catalytic  core  and contains  the  binding site  for  succinate.  The  other  part  of
the catalytic domain, which also forms an interface with the membrane anchor, is encod‐
ed by SDHB, a gene of eight exons located on chromosome 1p36.13.  SDHC on chromo‐
some  1q23.3  and  SDHD  on  chromosome  11q23.1  contain  six  and  four  exons,
respectively, and encode two hydrophobic proteins that anchor the complex to the mito‐
chondrial inner membrane. The link between SDH and neuroendocrine tumors was first
established in the year 2000, when germline mutations in SDHD were discovered in pa‐
tients  withfamilial  PGLs  [76].  SDHD mutations  were  subsequently  found also  in  appa‐
rently sporadic PCCs [77]  and PGLs [78]  as  well  as  in familial  PCCs [79].  Shortly after,
germline  mutations  were  also  identified  in  SDHB in  both  PCCs  and  PGLs  [80].  SDHC
mutations  were  reported  in  PGLs  in  2000  [81]  and  were  also  recently  found  in  PCCs
[82].  During  several  years,  homozygous  and  compound  heterozygous  mutations  in  the
gene encoding the fourth subunit, SDHA, were associated with a rare early-onset.
Germline mutations in the SDHx genes give rise to familial PCC–PGL syndrome, sometimes
only referred to as familial PGL. The syndrome can be divided into PGL1, PGL2, PGL3, and
PGL4, which are caused by mutations in SDHD, SDHAF2, SDHC, and SDHB respectively.
They are all inherited in an autosomal dominant manner but with varying penetrance.
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SDHD is putatively maternally imprinted and PGL1 is thus only passed on to children by
their father [83], although one exception of maternal transmission has been reported [84]. To
date, PGL2 has also only been diagnosed in individuals with an affected father, suggesting a
similar parent-of-origin-specific inheritance for SDHAF2 [85]. No specific PCC/PGL syn‐
drome has yet been described for SDHA mutations, but they seem to have a low penetrance
of PCC/PGL and do not seem to be associated with a familial presentation [86, 87]. The prev‐
alence of PCC/PGL syndrome is unknown, but a summary of the cases reviewed here (about
13% of all PCC/PGL cases) gives an estimate of 1:50 000 to 1:20 000, the majority represented
by PGL1 and PGL4. Apart from PCCs and PGLs, SDHB mutations have been associated
with renal cell carcinoma [88]. One SDHD mutation carrier with a renal cell tumor has also
been described, as well as a few cases of SDHB and SDHD patients with thyroid carcinoma
[88, 89]. In addition, mutations in SDHB, SDHC, and SDHD can give rise to the Carney–Stra‐
takis syndrome, characterized by the dyad of PGLs and gastrointestinal stromal tumors.
Very recently, SDHA mutations were also reported in two patients with gastrointestinal
stromal tumors but without PGLs [90].
SDHD mutations  (PGL1)  predispose  most  frequently  to  parasympathetic,  often  multifo‐
cal  PGLs,  but  also  to  sympathetic  PGLs  and  PCCs.  Several  national  and  multinational
studies have gathered information about tumor characteristics in patients with PCC/PGL
syndrome [69, 88-92].
4. New susceptibility genes in hereditary PCC/PGLs
4.1. Transmembrane protein 127(TMEM127)
TMEM127 is a gene of four exons located on 2q11.2, a locus identified as a PCC susceptibili‐
ty locus in 2005 [93]. The transmembrane protein was recently revealed to function as a tu‐
mor suppressor, and germline mutations in TMEM127 were detected in PCCs [72]. Qin et al.
also demonstrated that TMEM127 is a negative regulator of mechanistic target of rapamycin,
formerly mammalian target of rapamycin (mTOR), thus linking a critical signalling pathway
for cell proliferation and cell death to the initiation and development of PCC. Both missense
and nonsense mutations in TMEM127 have been reported. LOH of the gene was detected in
tumors of all tested mutation carriers, suggesting a classical two-hit model of inactivation.
So far,  no specific syndrome has been described for TMEM127. Other tumors,  including
MTC,  breast  cancer,  and  myelodysplasia,  have  been  identified  in  carriers  of  TMEM127
mutations,  but  a  causal  relationship  between  the  tumors  and the  mutations  remains  to
be  established  [94].  A  clear  family  history  in  only  a  fourth  of  the  patients  suggests  an
incomplete  penetrance,  and in  a  single  family,  the  penetrance  of  PCC was  64% by  the
age of 55 years [95].
Among 990 patients with PCC or PGL, negative for RET, VHL, and SDHB/C/D mutations,
TMEM127 mutations were identified in 20 (2.0%) of the cases, all of which had PCC [95].
Another study revealed one additional PCC patient with a TMEM127 mutation [96]. No
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TMEM127 mutations were detected in 129 sympathetic and 60 parasympathetic PGLs [93],
but in a recent study, germline missense variants were detected in two out of 48 patients
with multiple PGLs [97], one of which also displayed bilateral PCC. Summarizing the 23 re‐
ported patients, all but one (96%) had PCC and 39% had bilateral PCC.Two (9%) had PGL,
of which one had sympathetic and the other multiple parasympathetic PGLs. The mean age
at presentation was 43 years, and one patient (4%) displayed a malignant tumor.
4.2. MYC-associated factor X (MAX)
MAX is a gene of five exons, located on chromosome 14q23.3. It encodes a transcription fac‐
tor, MAX, that belongs to the basic helix–loop–helix leucine zipper (bHLHZip) family and
plays an important role in regulation of cell proliferation, differentiation, and death as a part
of the MYC/MAX/MXD1 network [98]. Members of the MYC family are proto-oncoproteins
and their expression correlates with growth and proliferation, whereas expression of MXD1
(also known as MAD) is associated with differentiation. Heterodimerization of MAX with
MYC family members results in sequence-specific DNA-binding complexes that act as tran‐
scriptional activators. In contrast, heterodimers of MAX with MXD1 family member repress
transcription of the same target genes by binding to the same consensus sequence and thus
antagonize MYC–MAX function. Interestingly, PC12 cells, derived from a rat PCC, express
only a mutant form of MAX incapable of dimerization, and a reintroduction of normal MAX
in these cells resulted in a repressed transcription and inhibited growth [99]. This suggests
that some tumors can grow in the absence of MYC–MAX dimers and may imply that MAX
can function as a tumor suppressor. A tumor suppressor role of MAX was most recently
confirmed when germline MAX mutations were discovered in PCC patients by next-genera‐
tion exome sequencing [73]. The mutations were missense, nonsense, splice site, or altering
the start codon, and immunohistochemical analysis confirmed the lack of full-length MAX
in the tumors. LOH of 14q, caused either by uniparental disomy or by chromosomal loss,
was seen in investigated tumors in agreement with classical tumor suppressor behaviour.
MAX mutations segregate with the disease in families with PCC [73], but no specific syn‐
drome has been described yet. A paternal origin of the mutated allele in investigated cases,
together with the absence of PCC in persons who inherited a mutated allele from their
mother, may suggest a paternal transmission of disease similar to that of PGL1 (SDHD) and
PGL2 (SDHAF2). MAX-associated PCCs and PGLs. Comino-Mendez et al. [73] reported 12
PCC patients with MAX mutations, of which three were discovered with exome sequencing
and four were relatives of those. The remaining five were found in a subsequent screening
of 59 PCC patients lacking mutations in other known susceptibility genes but suspected to
have hereditary disease (due to bilateral tumors, early age of onset, and/or familial antece‐
dents with the disease). Of the 12 patients, eight (67%) had bilateral PCC and the mean age
at presentation was 32 years. Notably, 25% of the patients (38% of the probands) showed
metastasis at diagnosis, suggesting that MAX mutations are associated with a high risk of
malignancy. So far, no studies on PGLs have been reported.
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5. Therapy of hereditary NETs
5.1. Multiple Endocrine Neoplasias
5.1.1. MEN1
The therapeutic management of MEN1-related hyperparathyroidism, as the only curative
therapy, is a surgical approach designed to remove all hyperfunctioning parathyroid tissue.
This approach consists of the sub-total or total parathyroidectomy followed by autotrans‐
plantation of parathyroid tissue in a normal forearm. This approach is clearly different sur‐
gery for sporadic hyperparathyroidism. The main consequence of a radical intervention is a
severe hypoparathyroidism, which requires treatment with high doses of calcium and vita‐
min D. This condition often leads to a difficulty in controlling the homeostasis of calcium
and a reduced quality of life for the possible occurrence of gastro-intestinal disorders. It is
not rare, in addition, the recurrence of hyperparathyroidism even after an apparently total
parathyroidectomy. Studies are in progress to evaluate the efficacy of calcium-mimetic
agents in the treatment of primary hyperparathyroidism in patients MEN1. Also somatosta‐
tin analogues, used in MEN1 subjects for the treatment of duodeno-pancreatic NETs, can
have a role in reducing the levels calcium and PTH [6, 10, 100, 101]. The therapy of duode‐
no-pancreatic NETs in MEN1 patients varies depending on the type and number of tumors.
Drug therapy involves the use of biologic therapy such as somatostatin analogues. For all
pancreatic tumors MEN1-dependent, the standard surgical treatment involves the distal
pancreatectomy combined with ultrasonography and intraoperative manual palpation. In
the case of tumors located in the head of the pancreas a duodeno-cephalo-pancreatectomy
second Whipple should be practiced. The treatment of choice of a solitary gastrinoma is enu‐
cleation. However, in MEN1patients gastrinomas are often multiple and/or metastatic and
the role of surgery, in these cases, it is debated [6, 10].
Several studies are ongoing to evaluate the efficacy of new drugs such as tyrosine kinase
and mTOR inhibitors for the treatment of metastatic pancreatic NETs.
The treatment of pituitary adenomas in MEN1 patients varies depending on the type of ade‐
noma and is the same treatment applied to the sporadic counterpart. Finally, even in the
case of a successful therapy, MEN1-related pituitary adenomas require a careful follow-up
because these neoplasms can easily recur [6, 10].
At the moment there is no known preventive surgical approach that can significantly im‐
prove outcomes in MEN1 patients, with the exception of prophylactic thymectomy to pre‐
vent the occurrence of the rare thymic carcinoid tumor, a tumor frequently malignant and
aggressive. This further supports the need to identify quite early the presence of malignan‐
cies, with a view to a better clinical management [10].
5.1.2. MEN2
The therapeutic strategy for MEN2 patients should be adapted to the clinical variant and the
type of mutation in the RET gene according to the risk levels.
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Subjects with the highest risk level have the most aggressive MTC and should have thyroi‐
dectomy with a central node dissection within the first six months of life and preferably
within the first month of life. In subjects classified as risk 2 level, thyroidectomy with re‐
moval of the posterior capsule should be performed before the age of five years. For subjects
with the lowest risk level (risk level 1) at this moment there are differing opinions on when
thyroidectomy should be performed. According to some authors, in fact, total thyroidecto‐
my with lymph node dissection of the central compartment should be practiced within the
fifth year of life, according to others such intervention should be performed later, but within
the tenth year of life. Other authors finally suggest to periodically perform the pentagastrin
stimulation test for calcitonin and to perform the surgery at the first positive test. In all cas‐
es, if a pheochromocytoma is present, total thyroidectomy should be performed after surre‐
nectomy to avoid a catecholaminergic crisis during the surgery [10].
Several studies are ongoing to evaluate the efficacy of new drugs such as tyrosine kinase in‐
hibitors for the treatment of metastatic MTC.
The treatment of choice in unilateral pheochromocytoma in MEN2 is laparoscopic adrena‐
lectomy [10].
The treatment for hyperparathyroidism in MEN2 includes the same surgical strategy as pro‐
vided in other syndromes associated with multiple parathyroid adenomas [10].
5.2. Familial paragangliomatosis
The treatment of choice for FPGL is surgical removal of paraganglioma / pheochromocyto‐
ma, after preparation with α-and β-adrenergic blocking drugs in order to improve the peri-
operative hemodynamic stability. In the case of benign pheochromocytomas/
paragangliomas the percentage of full resolution with surgery is approximately 100% [102].
Early intervention and timely manner helps to minimize the morbidity and mortality of this
disease.For malignant pheochromocytomas/paragangliomas are available chemo- and radio-
therapic approaches. Studies are in progress to evaluate the efficacy of tyrosine kinase inhib‐
itors, such as sunitinib, for the treatment of malignancies. At the moment, there is no specific
treatment prior to the onset of hereditary pheochromocytomas/paragangliomas [103, 104].
Early diagnosis and a periodic follow-up are the best approaches for the management and
better outcome because of the possible malignant degeneration, especially in the forms asso‐
ciated with SDHB gene mutations [105].
6. Impact of genetic screening on natural history and clinical
management
In the last years, the growing number of subjects with hereditary NET who is diagnosed at a
pre-clinical stage is changing the clinical picture of these tumors. Until now the clinical fea‐
tures and natural history of hereditary NETs were based on data from patients with clinical
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evidence of disease. With the identification of specific genes responsible for the develop‐
ment of hereditary NETs, more and more subjects are recognized to be carriers of NET-relat‐
ed gene mutations. Pre-clinical genetic screening in asymptomatic first-degree relatives of
patients with hereditary NET syndromes leads to detect these neoplasias at an early stage,
even when subjects are still asymptomatic.
The genetic risk assessment can provide crucial information on the patient’s future risk for
tumors and the assessed risk to their family members. An early genetic diagnosis in asymp‐
tomatic subjects is recommended to identify subjects at risk to develop one of the above
mentioned hereditary NET syndromes as early as possible before the occurrence of clinical
manifestations, in order to improve their long-term outcome and to ensure a survival and
quality of life similar to that observed in the general population [5].
Since the screening for early symptoms starts, parents should be given counseling in the
process of considering the test for their child. Support by a psychosocial worker may be a
valuable part of the counseling.
Early detection of tumors in patients with hereditary NETs could encourage the use of cyto‐
static drugs for blocking the development of lesions in early stage or even in a pre-clinical
phase, before that they are developed. Several studies are underway to demonstrate the an‐
ti-proliferative effect of these drugs.
7. Clinical, biochemical and instrumental monitoring of patients with
hereditary NETs
Periodical evaluations in reference health centers are necessary in subjects with hereditary
NETs in a pre-clinical phase (before the appearance of tumors), especially young subjects, to
early detect tumors and prevent complications and risk of malignant transformation.
7.1. Multiple Endocrine Neoplasias
MEN1 patients and MEN1 carriers have to be monitored periodically.
The new guidelines for periodic clinical, biochemical and morphological monitoring of
MEN1 patients is shown in Table 3 [106].
7.2. Familial paragangliomatosis
Patients with FPGL and SDHx carriers have to be monitored periodically to detect the pres‐
ence of new lesions and to rule out a malignancy. Periodic clinical examination, laboratory
tests measuring plasma free metanephrines, 24-hour urine catecholamines and metanephr‐
ines, imaging techniques including neck, skull base and abdomen/pelvis CT-scan and/or
MRI and functional imaging techniques including somatostatin receptor scintigraphy and
MIBG scintigraphy are mandatory in all patients with FPGL.
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Tumor Age to begin (yrs) Biochemical tests annually Imaging tests (timeinterval)
Parathyroid adenoma 8 Calcium, PTH -
Gastrinoma 20 Gastrin -
Insulinoma 5 Glucose, insulin -
Other enteropancreatic
NETs 10 CgA, PP, VIP, glucagon MRI, CT or EUS (annually)
Anterior pituitary 5 PRL, IGF-1 MRI (every 3 yrs)
Foregut carcinoid 20 - CT or MRI (every 1-2 yrs)
PTH: parathyroid hormone; CgA: chromogranin-A; PP: pancreatic polypeptide; VIP: vasoactive intestinal peptide; PRL:
prolactin; IGF-1: insulin-like growth factor 1; MRI: magnetic resonance imaging; CT: computed tomography; EUS:
echoendoscopy ultrasonography.
Table 3. Periodic clinical, biochemical and morphological monitoring of MEN1 patients
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